Medication-assisted Treatment (MAT) Market Share

  • Report ID: 5814
  • Published Date: Nov 28, 2025
  • Report Format: PDF, PPT

Medication-assisted Treatment (MAT) Market - Regional Analysis

North American Market Insights

Medication-assisted Treatment market in the North America region is anticipated to hold the largest share of about 45% by the end of 2035. The regional growth is attributed to the factor that government, healthcare, organizations, and philanthropic entities in the region have allocated increased funding and resources to support MAT initiatives. This financial backing has enabled the expansion of treatment facilities, training programs, and public awareness campaigns. According to the National Institute on Drug Abuse, methadone treatment, including medication and integrated psychosocial & medical support services cost USD 6, 55, 20 per year in the US. In addition, the region has recognized the importance of MAT in treating opioid addiction and regulatory frameworks have been adapted to facilitate the integration of MAT into mainstream healthcare, ensuring better access to these treatments for individuals in need and stimulate the market in the region.

European Market Insights

The Europe medication-assisted treatment market is estimated to the second largest revenue share of about 30% by the end of 2035. The market’s expansion can be attributed to the multidisciplinary approach adopted by the European healthcare system to deal with substance disorders. MAT is integrated into this approach, combining medications with counseling and psychosocial support to address the complex nature of substance use disorders comprehensively. In addition, Community-based MAT programs have been established in various European regions. For example, a Harm reduction program encompasses interventions and policies that seek to mitigate the health, social, and economic harms of drug use to individuals, communities, and societies.  These initiatives focus on providing localized and accessible treatment options, emphasizing the importance of community involvement and support in the recovery process which further stimulate the medication-assisted treatment market in the region.

Medication-assisted Treatment (MAT) Market Share

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of medication-assisted treatment is estimated at USD 12.09 billion.

The global medication-assisted treatment market size crossed USD 11.2 billion in 2025 and is likely to register a CAGR of over 8.8%, exceeding USD 26.03 billion revenue by 2035.

By 2035, the North America region is projected to secure about 45% share in the medication-assisted Treatment Market, supported by intensified funding for MAT programs, expanded treatment capacity, and broader regulatory integration into mainstream healthcare owing to increased institutional backing.

Key players in the market include Indivior PLC, Mallinckrodt Pharmaceuticals, Titan Pharmaceuticals Inc., Alkermes plc, Orexo AB, Mylan N.V., Teva Pharmaceutical Industries Ltd., Lupin Limited, Hikma Pharmaceuticals PLC, Novartis AG.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos